

## CHAPTER 3.3.6.

# AVIAN TUBERCULOSIS

---

### SUMMARY

**Description of the disease:** Avian tuberculosis, or avian mycobacteriosis, is an important disease that affects companion, captive exotic, wild and domestic birds and mammals. The disease is most often caused by *Mycobacterium avium* subsp. *avium* (*M. a. avium*). However more than ten other mycobacterial species have been reported to infect birds. The most significant cause of poultry disease is *M. a. avium*.

Clinical signs of the disease vary depending on the organs involved. The classical presentation is characterised by chronic and progressive wasting and weakness. Diarrhoea is common. Some birds may show respiratory signs and occasionally sudden death occurs. Some birds may develop granulomatous ocular lesions.

*Mycobacterium tuberculosis* (gene IS61001) is less commonly the cause of infection in birds, often as a result of transmission from pet bird owners.

Members of *M. avium* complex: *M. avium* subsp. *hominissuis* (serotypes 4–6, 8–11 and 21; lacking gene segment IS901 and containing segment IS1245) and *M. intracellulare* (serotypes 7, 12–20 and 22–28; lacking both IS901 and IS1245) can also infect an extensive range of mammals such as swine, cattle, deer, sheep, goats, horses, cats, dogs, and exotic species. In humans, all members of *M. avium* complex and *M. genavense* are capable of inducing a progressive disease that is refractory to treatment, mostly in immunocompromised patients.

All manipulations involving the handling of open live cultures or of material from infected birds must be carried out with appropriate biorisk management.

Diagnosis of avian tuberculosis in birds depends on the demonstration of the above-mentioned mycobacterial species in live or dead birds, or the detection of an immune response, cellular or humoral, culture examination, or gene segments IS6110, IS901 and IS1245 by polymerase chain reaction (PCR) in the excretions or secretions of live birds.

**Detection of the agent:** Where clinical signs of avian tuberculosis are seen in the flock, or typical tuberculous lesions are present in birds at necropsy, the demonstration of acid-fast bacilli in smears or sections made from affected organs is sufficient for a quick positive diagnosis. If acid-fast bacilli are not found, but typical tuberculous signs or lesions are present in the birds, culture of the organism must be attempted. PCR could also be carried out directly on tissue samples. Any acid-fast organism isolated should be identified by nucleic-acid-based tests, or chromatographical (e.g. high performance liquid chromatography [HPLC]) criteria; serotyping of isolates of *M. avium* complex members or PCR for IS6110, IS901 and IS1245 could be performed.

**Tuberculin test and serological tests:** These tests are normally used to determine the prevalence of disease in a flock, or to detect infected birds. When used to detect the presence of avian tuberculosis in a flock, they should be supported by the necropsy of any birds that give positive reactions.

In domestic fowl, the tuberculin test in the wattle is the test of choice. This test is less useful in other species of bird. A better test, especially in waterfowl, is the whole blood stained-antigen agglutination test. It is more reliable and has the advantage that it will give a result within a few minutes, while the bird is still being held.

**Requirements for vaccines and diagnostic biologicals:** No vaccines are available for use in birds. Avian tuberculin purified protein derivative (PPD) is the standard preparation for use in the tuberculin test of domestic poultry. Avian PPD is also used as a component in the comparative intradermal tuberculin test in cattle (see Chapter 3.1.13 Mammalian tuberculosis [infection with *Mycobacterium tuberculosis* complex]).

## A. INTRODUCTION

Several mycobacterial species can be involved in the aetiology of avian tuberculosis and avian mycobacteriosis. Avian tuberculosis is most commonly produced by infection with *Mycobacterium avium* subsp. *avium* (serotypes 1, 2 and 3; containing specific gene segment IS901 and nonspecific segment IS1245) and less frequently by *M. genavense* (Guerrero *et al.*, 1995; Pavlik *et al.*, 2000; Tell *et al.*, 2001). Avian mycobacteriosis is caused by other two members of *M. avium* complex: *M. avium* subsp. *hominissuis* (serotypes 4–6, 8–11 and 21; lacking gene segment IS901 and containing segment IS1245) and *M. intracellulare* (serotypes 7, 12–20 and 22–28; lacking both gene segments IS901 and IS1245) and by *M. intracellulare*, *M. scrofulaceum*, *M. fortuitum* and other potentially pathogenic mycobacterial species. Under some circumstances, an extensive range of mammalian species, such as swine, cattle, deer, sheep, goats, horses, cats, dogs, and exotic animals can be infected (Dvorska *et al.*, 2004; Mijs *et al.*, 2002; Shitaye *et al.*, 2009; Tell *et al.*, 2001; Thorel *et al.*, 1997; 2001). *Mycobacterium tuberculosis* and *M. bovis* are less common as causal agents of tuberculosis in birds (Tell *et al.*, 2001).

*Mycobacterium avium* species consists of four subspecies: *M. avium* subsp. *avium*, *M. avium* subsp. *hominissuis*, *M. avium* subsp. *silvaticum*, and *M. avium* subsp. *paratuberculosis* (Mijs *et al.*, 2002; Thorel *et al.*, 1990). The latter is the causal agent of Johne's disease, or paratuberculosis, in ruminants and other mammalian species (see Chapter 3.1.16 *Paratuberculosis [Johne's disease]*). *Mycobacterium a. silvaticum*, which like *M. avium* subsp. *paratuberculosis* grows *in-vitro* only on media with Mycobactin, can cause avian tuberculosis in wood pigeon (Thorel *et al.*, 1990).

All *M. a. avium* isolates from birds and mammals, including humans, have a multiple repetitive sequence IS901 in their genome and produce a characteristic three-band pattern in IS1245 restriction fragment length polymorphism (RFLP) as described and standardised previously (Dvorska *et al.*, 2003; Ritacco *et al.*, 1998). This repetitive sequence is also present in *M. a. silvaticum* and RFLP analysis can help with identification. IS901 has only been detected in *M. avium* strains with serotypes 1, 2 and 3 (Pavlik *et al.*, 2000; Ritacco *et al.*, 1998) that are apparently more pathogenic to birds than other serotypes (Tell *et al.*, 2001). On the basis of genetic and phenotypic differences it has recently been proposed to differentiate *M. a. avium* into two subspecies based on the target organism: *M. a. hominissuis* for human and porcine isolates and *M. a. avium* for bird-type isolates (Mijs *et al.*, 2002). *Mycobacterium a. hominissuis* has polymorphic multiband IS1245 RFLP patterns and is able to grow between 24 and 45°C (Mijs *et al.*, 2002; Van Soolingen *et al.*, 1998). It is worth noting that the typical features of bird-isolates, the three-band pattern in IS1245 RFLP and presence of IS901, have also been found in cervine and bovine isolates of *M. a. avium* (O'Grady *et al.*, 2000).

Avian tuberculosis in birds is most prevalent in gallinaceous poultry and in wild birds raised in captivity. Turkeys are quite susceptible, but duck, geese and other water birds are comparatively resistant. The practices of allowing poultry to roam at large on the farm (free range) and of keeping the breeders for several years are conducive to the spread of the causal agent of avian tuberculosis among them. Infected individuals and contaminated environment (water and soil) are the main source of infection. The above-mentioned mycobacterial species causing avian tuberculosis can survive for several months in the environment (Dvorska *et al.*, 2007; Kazda *et al.*, 2009; Shitaye *et al.*, 2008; Tell *et al.*, 2001).

In most cases, infected birds show no clinical signs, but they may eventually become lethargic and emaciated. Many affected birds show diarrhoea, and comb and wattles may regress and become pale. Affected birds, especially gallinaceous poultry, are usually older than 1 year. Some show respiratory signs and sudden death may occur, dyspnoea is less common, and granulomatous ocular lesions (Pocknell *et al.*, 1996) as well as skin lesions have been reported. Under intensive husbandry conditions, sudden death may occur, often associated with severe lesions in the liver; such lesions are easily observed at post-mortem examination (Tell *et al.*, 2001).

The primary lesions of avian tuberculosis in birds are nearly always in the intestinal tract. Such lesions take the form of deep ulcers filled with caseous material containing many mycobacterial cells, and these are discharged into the lumen and appear in the faeces. Before the intestinal tract is opened, the ulcerated areas appear as tumour-like masses attached to the gut wall, but when the intestine is opened, the true nature of the mass becomes evident. Typical caseous lesions are nearly always found in the liver and spleen, and these organs usually are greatly enlarged because of the formation of new tuberculous tissue. The lungs and other tissues are ordinarily free from lesions even in advanced cases (Tell *et al.*, 2001; Thorel *et al.*, 1997).

Among domestic animals (mammals), domestic pigs (*Sus scrofa f. domesticus*) are the most susceptible to avian tuberculosis. Usually, no clinical manifestations are observed in such animals. Avian tuberculosis is suspected when tuberculous lesions are found in the head and mesenteric lymph nodes on meat inspection after slaughter. Findings of tuberculous lesions that involve other organs (liver, spleen, lungs, etc.) are rare, usually occurring at the advanced stage of the disease. *Mycobacterium a. avium* accounted for up to 35% of the *Mycobacteria* isolated from such tuberculous lesions (Dvorska et al., 1999; Pavlik et al., 2003, 2005; Shitaye et al., 2006). Unlike the other species mentioned previously, cattle are highly resistant to the causative agent of avian tuberculosis, and tuberculous lesions are detected in head lymph nodes, or occasionally in liver lymph nodes, only on meat inspection. *Mycobacterium a. avium* can be successfully isolated from tuberculous lesions in mesenteric lymph nodes from juvenile cattle: the isolation rate from cattle under 2 years of age was 34.4% in contrast to 13.0% from cattle over 2 years of age (Dvorska et al., 2004).

It is essential to bear in mind that all members of *M. avium* complex and *M. genavense* are capable of giving rise to a progressive disease in humans that is refractory to treatment, especially in immunocompromised individuals (Pavlik et al., 2000; Tell et al., 2001). Members of *Mycobacterium avium* complex are classed in Risk Group 2 for human infection and should be handled with appropriate measures as described in Chapter 1.1.4 *Biosafety and biosecurity: Standard for managing biological risk in the veterinary laboratory and animal facilities*. Biocontainment measures should be determined by risk analysis as described in Chapter 1.1.4.

## B. DIAGNOSTIC TECHNIQUES

Table 1. Test methods available for the diagnosis of avian tuberculosis and their purpose

| Method                                     | Purpose                           |  |                                    |                                |  |   |
|--|-----------------------------------|--|------------------------------------|--------------------------------|--|---|
|  | Population freedom from infection | Individual animal freedom from infection prior to movement | Contribute to eradication policies | Confirmation of clinical cases | Prevalence of infection – surveillance | Immune status in individual animals or populations post-vaccination |
| Identification of the agent <sup>(a)</sup> |                                   |  |                                    |                                |  |   |
| Ziehl–Neelsen staining                     | –                                 | –  | –                                  | ++                             | –                                      | –   |
| Culture                                    | –                                 | –  | –                                  | ++                             | –                                      | –   |
| Haemagglutination (stained antigen)        | +                                 | +++  | +                                  | –                              | ++                                     | –   |
| PCR  | ++                                | +  | –                                  | +++                            | –                                      | –   |
| Detection of immune response               |                                   |  |                                    |                                |  |   |
| Tuberculin test                            | ++                                | +++  | +                                  | –                              | ++                                     | –   |

Key: +++ = recommended for this purpose; ++ recommended but has limitations;

+ = suitable in very limited circumstances; – = not appropriate for this purpose.

PCR = polymerase chain reaction.

<sup>(a)</sup>A combination of agent identification methods applied on the same clinical sample is recommended.

### 1. Identification of the agent

If there is a characteristic history of avian tuberculosis in a flock and typical lesions are found in birds at post-mortem, the detection of acid-fast bacilli (AFB) in smears or sections from affected organs, stained by the Ziehl–Neelsen method, is normally sufficient to establish a diagnosis. Occasionally a case will occur, presumably as a result of large infecting doses giving rise to acute overwhelming disease, in which affected organs, most obviously the liver, have a ‘morocco leather’ appearance with fine greyish or yellowish mottling. In such cases AFB may not be found, but careful inspection will reveal parallel bundles of brownish refractile bacilli. Prolongation of the hot carbolfuchsin stage of Ziehl–Neelsen staining to 10 minutes will usually reveal that these are indeed AFB, with unusually high resistance to penetration of the stain. DNA probes and polymerase chain reaction (PCR) techniques have been

used to identify the agent at the species and subspecies level. Traditionally, *M. a. avium* is separated from common nonchromogenic slow-growing organisms by their ability to grow at 42°C (*M. a. avium*). *Mycobacterium genavense* is particularly fastidious and has special requirements for growth and identification (Shitaye *et al.*, 2010).

### 1.1. Culture

If there is a characteristic flock history and suggestive lesions are found at necropsy, but no AFB are seen in smears or sections, an attempt must be made to isolate the causative organism from the necropsy material. Liver or spleen is usually the best organ to use, but if the carcass is decomposed, bone marrow may prove more satisfactory as it could be less contaminated. As with culture of *M. bovis*, non-sterile specimens need to be processed with detergent, alkali or acid to eliminate rapidly growing microorganisms before culture (see Chapter 3.1.13 *Mammalian tuberculosis [infection with Mycobacterium tuberculosis complex]*). *Mycobacterium a. avium* grows best on media such as Lowenstein–Jensen, Herrold's medium, Middlebrook 7H10 and 7H11 or Coletsos, with 1% sodium pyruvate added. It may occasionally be necessary to incorporate mycobactin, as it is used for the isolation of *M. a. paratuberculosis* and *M. a. silvaticum*. Growth may be confined to the edge of the condensation water. Cultures should be incubated for at least 8 weeks. Typically *M. a. avium* produces 'smooth' colonies within 2–4 weeks; rough variants do occur. Shorter incubation times can be achieved using the liquid culture BACTEC system or automated fluorescent MGIT 960 culture system. *Mycobacterium a. avium* can also be detected in massively infected tissue by a conventional PCR, which also allows acceleration of the pathogen identification (Moravkova *et al.*, 2008). Currently, direct detection and quantification of *M. a. avium* using IS901 quantitative real-time PCR can be considered as the best method (despite its rather high cost per test) (Kaevska *et al.*, 2010; Slana *et al.*, 2010).

For *M. genavense*, the optimal solid medium is Middlebrook 7H11 medium acidified to pH 6 and supplemented with blood and charcoal (Realini *et al.*, 1999). The incubation period at 37°C should be extended for at least 6 months (Shitaye *et al.*, 2010).

Typing of mycobacteria to the species and subspecies level requires a specialised laboratory. Conventional biochemical tests for species identification are lengthy and fail to distinguish between *M. avium* and *M. intracellulare*. Thus, a miscellaneous group of mycobacteria that includes both species is usually classified under the denomination of *M. avium* complex (MAC). Seroagglutination, which is based on sugar residue specificity of surface glycopeptidolipids, allows classification of *M. avium* complex (MAC) organisms into 28 serovars (Wolinsky & Schaefer, 1973). More sophisticated typing methods directed at cell-wall-specific targets are currently available, such as enzyme-linked immunosorbent assays with monoclonal antibodies to major serovars, and high performance liquid chromatography (HPLC). Serovars 1 to 6, 8 to 11 and 21 are currently ascribed to *M. a. avium* and *M. a. hominissuis*, and serovars 7, 12 to 20 and 25 to *M. intracellulare*. However, no consensus was achieved on other serovars, and some isolates cannot be typed (Inderlied *et al.*, 1993). Avian tuberculosis in birds is caused by *M. a. avium* types 1, 2, or 3. If the isolate is not one of these three serotypes, further identification tests (IS901 PCR) must be carried out. However, it should be borne in mind that superficial tuberculous lesions in caged birds, especially psittacines, may be caused by *M. tuberculosis* and IS6110 PCR should be used for precise identification.

### 1.2. Nucleic acid recognition methods

Specific and reliable genetic tests for speciation are currently available (Saito *et al.*, 1990). Commercial nucleic acid hybridisation probes have become a reference method for distinction between *M. avium* and *M. intracellulare* cultures. *M. genavense* can also be distinguished with these tests. A further probe that covers the whole MAC was also developed, as genuine MAC strains have been described that fail to react with specific *M. avium* and *M. intracellulare* probes (Soini *et al.*, 1996). Nevertheless identification errors were reported due to the cross-reactivity, which may have serious consequences (van Ingen *et al.*, 2009). Various in-house molecular methods have been reported for the identification of mycobacterial cultures, including MAC. A multiplex PCR method for differentiating *M. avium* from *M. intracellulare* and *M. tuberculosis* complex has some advantages (Cousins *et al.*, 1996). 16S rRNA sequencing (Kirschner *et al.*, 1993) may also be used. Culture-independent in-house molecular tests have been developed for the detection and identification of species belonging to the *M. avium* complex directly from samples (Kaevska *et al.*, 2010).

*Mycobacterium a. avium*, the causative agent of avian tuberculosis (Thorel *et al.*, 1990), previously designated as *M. avium* species only, is assigned to serotypes 1 to 3 within the *M. avium* complex of 28 serotypes (Wolinsky & Schaefer, 1973). As revealed by molecular biological studies, the detected insertion sequence IS901 (Kunze *et al.*, 1992) is possessed not only by the isolates of the above-named serotypes, but also by isolates, virulent for birds, that could not be typed because agglutination occurred (Pavlik *et al.*, 2000). In epidemiological studies, a standardised IS901 RFLP methods replaced serotyping (Dvorska *et al.*, 2003).

## 2. Immunological methods

Tests used for export depend on the importing requirement of individual countries. In the main, the tuberculin test or the haemagglutination (stained antigen) test are most frequently used for export testing of poultry.

### 2.1. Tuberculin test

The tuberculin test is most widely used test in domestic fowl, and the only test for which an international standard for the reagent exists. The tuberculin is the standard avian purified protein derivative (PPD). Birds are tested by intradermal inoculation in the wattle with 0.05 ml or 0.1 ml of tuberculin (containing approximately 2000 International Units [IU]), using a very fine needle of approximately 10 mm × 0.5 mm. The test is read after 48 hours and a positive reaction is any swelling at the site, from a small firm nodule approximately 5 mm in diameter to gross oedema extending into the other wattle and down the neck. With practice, even very small wattles on immature birds can be inoculated successfully. However, in immature birds the comb may be used, although results are not so reliable. Tuberculin testing of the wattle in turkeys is much less reliable than in the domestic fowl. Inoculation in the wing web has been recommended as being more efficient, but this is still not as good as for domestic fowl. Other birds may also be tested in the wing web, but results are not generally satisfactory. The bare ornamental skin areas on Muscovy ducks and some species of pheasant can be used, but reliability is doubtful and interpretation difficult. Testing in the foot web of waterfowl has also been described; the test is not very sensitive and is often complicated by infections of the inoculation site.

In pheasants, the tuberculin test can be performed in either of two ways. In the first, 0.05 ml or 0.1 ml of tuberculin is injected into the skin of the lower eyelid. A positive result is indicated by marked swelling at the site of injection after 48 hours. Alternatively, 0.25 ml of tuberculin is injected into the thoracic muscles and the birds are observed for 6–10 hours. Infected birds will show signs of depression and keep aside from the flock, and there may be cases of sudden death. No clinical signs will be provoked in uninfected birds.

### 2.2. Stained antigen test

#### 2.2.1. Preparation of the antigen

An antigen stained with 1% malachite green is used for the rapid whole blood plate agglutination test (Rozanska, 1965). The strain used for preparation of the stained antigen must be smooth and not autoagglutinate in saline suspension. It must conform to the characteristics of *M. a. avium*.

A strain that will detect infection with any serotype is recommended to be used instead of the specific serotype that is most likely to be encountered (in Europe serotype 2 for domestic fowl, serotype 1 for waterfowl, and birds and swine in the USA). It may be preferable to use a strain that is highly specific for the serotype it detects. The specificity of strains can be determined only by testing them as antigens, although in general, a serotype 2 antigen will always detect serotype 3 infection and vice versa. Serotype 1 strains appear to detect more often a wide spectrum of infection, and will frequently also detect infections with mycobactin-dependent mycobacteria or *M. a. silvaticum*. There is no reason not to use a culture containing more than one strain of *M. a. avium*, provided that it shows the desired properties of sensitivity and specificity. Consistency of results between batches will be easier with the use of pure cultures.

The organism should be grown in a suitable liquid medium, such as Middlebrook 7H9 containing 1% sodium pyruvate for better growth. Good growth should be obtained in approximately 7 days. The liquid culture is used as seed for bulk antigen preparation.

Antigen for agglutination tests is best grown on solid medium, such as Löwenstein–Jensen or 7H11, containing 1% sodium pyruvate instead of glycerol, using Roux flasks or large bottles. The use of solid medium maximises the chance of detecting any contamination, and antigens grown in some liquid media are not agglutinated by specific antibody. Liquid seed culture should be diluted (on the basis of experience) to give discrete colonies on the solid medium. This will usually give the best yield, and again increases the chance of detecting contamination. About 10 ml of inoculum will usually be enough to allow it to wash over the whole surface, and provide sufficient moisture to keep the air in the bottle near 100% humidity.

The bottles are incubated at 37°C, and good growth should be obtained in 14–21 days with most strains. The antigen is harvested by the addition of sterile glass beads and twice the volume of sterile normal saline (containing 0.3% formalin) as was used to inoculate the bottle. The bottle is then shaken gently to wash off all the growth and the washing is collected into a sterile bottle and re-incubated at 37°C for 7 days. The killed bacilli are then washed twice in sterile normal saline with 0.2% formalin by centrifugation and re-suspension. This sequence is safer than the original method in which the washing was carried out before the incubation that kills the organisms. Finally bacilli are again centrifuged and re-suspended in sterile normal saline containing 0.2% formalin and 0.4% sodium citrate, to a concentration of about  $10^{10}$  bacteria per ml. This corresponds to a concentration ten times that which matches tube No. 4 on McFarland's scale.

Cultures for antigen should be inspected for contamination daily for the first 5 days of incubation. The suspension made from the culture washings is also re-examined microscopically (for likely contaminants such as yeasts), and rechecked by culture to ensure that the formalin has killed the mycobacteria.

### 2.2.2. Validation of the antigen

Cultures should be checked by Gram staining for the presence of organisms other than mycobacteria.

One or more batches for agglutinating antigen must be tested for efficacy in naturally or artificially infected tuberculous birds by comparison with a standard preparation of known potency. The potency relative to that of the standard preparation must not differ significantly from that declared on the label. Each bottle of antigen must be tested with normal chicken serum (to detect autoagglutination) and *M. a. avium* positive chicken serum of low and high antibody content. This should be done, where possible, alongside a previous batch of stained antigen. Those bottles that give satisfactory agglutination reactions with the antisera can now be pooled and the antigen stained. This is done by the addition of 3 ml of 1% malachite green solution per 100 ml of suspension. If possible, the stained antigen should now be checked using whole blood just as the unstained antigen was tested with serum. The agglutinating antigen should keep for at least 6 months in the refrigerator at 4°C, and much longer if frozen at –20°C or below. If a batch has not been used for a long time it should be rechecked, especially for autoagglutination.

The only safety test needed is the culture test of the unwashed antigen after 7 days of incubation, to ensure that all the bacilli are dead.

### 2.2.3. Test procedure

The stained-antigen agglutination test has been used with good results, especially in both domestic and ornamental waterfowl. A drop (0.05–0.1 ml) of the antigen is mixed with the same volume of fresh whole blood, obtained by venipuncture, on a white porcelain or enamel tile. The mixture is rocked for 2 minutes and examined for agglutination. The agglutination may be coarse, in which case it is obvious, or quite fine, in which case it may be most clearly seen as an accumulation of the malachite-green-stained antigen around the edge of the drop, leaving the centre a normal blood-red colour. This test is especially useful for screening large flocks for immediate culling, and therefore has advantages over the tuberculin test for the control of the disease, even in domestic fowl. It has also been claimed that in domestic fowl it is more reliable than the tuberculin test.

## Note on limitation of use

Neither the tuberculin test with avian tuberculin nor the stained-antigen agglutination test is likely to be of any value in cases of *M. tuberculosis* infection in caged birds.

## C. REQUIREMENTS FOR DIAGNOSTIC BIOLOGICALS

### 1. Background

No vaccines are available.

Avian tuberculin is a preparation of purified protein derivatives (PPD) made from the heat-treated products of growth of *M. a. avium*. It is used by intradermal injection to reveal delayed hypersensitivity as a means of identifying birds infected with or sensitised to the same species of tubercle bacillus. It is also used as an aid to differential diagnosis in the comparative intradermal tuberculin test for bovine tuberculosis (see Chapter 3.1.13).

The general principles as given in Chapter 1.1.8 *Principles of veterinary vaccine production* should be followed for injectable diagnostic biologicals such as tuberculin. The standards set out here and in chapter 1.1.8 are intended to be general in nature and may be supplemented by national and regional requirements.

### 2. Outline of production and minimum requirements for tuberculin production

#### 2.1. Characteristics of the seed

##### 2.1.1. Biological characteristics of the master seed

Strains of *M. a. avium* used to prepare seed cultures should be identified as to species by appropriate tests. The strains recommended by the European Union (EU), for example, are D4ER and TB56. Reference may also be made to the World Health Organization (1987).

##### 2.1.2. Quality criteria (sterility, purity, freedom from extraneous agents)

Seed cultures should be shown to be free from contaminating organisms and to be capable of producing tuberculin with sufficient potency. The necessary tests are described below.

#### 2.2. Method of manufacture

##### 2.2.1. Procedure

The seed material is kept as a stock of freeze-dried cultures. If the cultures have been grown on solid media, it will be necessary to adapt the organism to grow as a floating culture. This is most easily accomplished by incorporating a piece of potato in the flasks of liquid medium (e.g. Watson Reid's medium). When the culture has been adapted to liquid medium, it can be maintained by passage at 2–4-week intervals (Angus, 1978; Haagsma & Angus, 1995).

The organism is cultivated in modified Dorset-Henley's synthetic medium, then killed by heating in flowing steam and filtered to remove cells. The protein in the filtrate is precipitated chemically (ammonium sulphate or trichloroacetic acid [TCA] are used), washed and resuspended. An antimicrobial preservative that does not give rise to false-positive reactions, such as phenol (not more than 0.5% [w/v]), may be added. Mercurial derivatives should not be used. Glycerol (not more than 10% [w/v]) or glucose (2.2% [w/v]) may be added as a stabiliser. The product is dispensed aseptically into sterile neutral glass containers, which are then sealed to prevent contamination. The product may be freeze-dried.

##### 2.2.2. Requirements for ingredients

The production culture substrate must be shown to be capable of producing a product that conforms to the standards of the European Pharmacopoeia (2000) or other international standards. It must be free from ingredients known to cause toxic or allergic reactions.

### 2.2.3. In-process controls

The production flasks, inoculated from suitable seed cultures, are incubated for the appropriate time period. Any flasks showing contamination or grossly abnormal growth should be discarded after autoclaving. As incubation proceeds, the surface growth of many cultures becomes moist and may sink into the medium or to the bottom of the flask. In PPD tuberculin, the pH of the dissolved precipitate (the so-called concentrated tuberculin) should be pH 6.6–6.7. The protein level of the PPD concentrate is determined by the Kjeldahl method. Total nitrogen and trichloroacetic acid precipitable nitrogen are usually compared.

### 2.2.4. Final product batch tests

#### i) Sterility

Sterility testing is generally performed according to the European Pharmacopoeia (2000) or other guidelines (see also Chapter 1.1.9 *Tests for sterility and freedom from contamination of biological materials intended for veterinary use*).

#### ii) Identity

One or more batches of tuberculin may be tested for specificity together with a standard preparation of bovine tuberculin by comparing the reactions produced in guinea-pigs sensitised with *M. bovis* using a procedure similar to that described in Section C.2.2.4.iv. In guinea-pigs sensitised with *M. bovis*, the potency of the preparation of avian tuberculin must be shown to be not more than 10% of the potency of the standard preparation of bovine tuberculin used in the potency test.

#### iii) Safety

Tuberculin PPD can be examined for freedom from living mycobacteria using the culture method described previously. This culture method, which does not require use of animals, is used in many laboratories and its use is encouraged over the use of animals for this purpose. The following is the previously described method, using experimental animals, to evaluate safety of PPD. Two guinea-pigs, each weighing not less than 250 g and that have not been treated previously with any material that will interfere with the test, are injected subcutaneously with 0.5 ml of the tuberculin under test. No abnormal effects should occur within 7 days.

Tests on tuberculin for living mycobacteria may be performed either on the tuberculin immediately before it is dispensed into final containers or on samples taken from the final containers themselves. A sample of at least 10 ml must be taken and this must be injected intraperitoneally or subcutaneously into at least two guinea-pigs, dividing the volume to be tested equally between the guinea-pigs. It is desirable to take a larger sample, 50 ml, and to concentrate any residual mycobacteria by centrifugation or membrane filtration. The guinea-pigs are observed for at least 42 days, and are examined macroscopically at post-mortem. Any lesions found are examined microscopically and by culture. Each filled container must be inspected before it is labelled, and any showing abnormalities must be discarded.

A test for the absence of toxic or irritant properties must be carried out according to the specifications of the European Pharmacopoeia (2000).

To test for lack of sensitising effect, three guinea-pigs that have not previously been treated with any material that could interfere with the test are each injected intradermally on each of three occasions with the equivalent of 500 IU of the preparation under test in a 0.1 ml volume. Each guinea-pig, together with each of three control guinea-pigs that have not been injected previously, is injected intradermally 15–21 days after the third injection with the same dose of the same tuberculin. The reactions of the two groups of guinea-pigs should not be significantly different, when measured 24–28 hours later.



## iv) Batch potency

The potency of avian tuberculin is determined in guinea-pigs sensitised with *M. a. avium*, by comparison with a standard preparation calibrated in IU.

Use no fewer than nine albino guinea-pigs, each weighing 400–600 g. Sensitise the guinea-pigs by administering to each, by deep intramuscular injection, a suitable dose of inactivated or live *M. a. avium*. The test is performed between 4 and 6 weeks later as follows: Shave the guinea-pigs' flanks so as to provide space for three-to-four injections on each side. Prepare at least three dilutions of the tuberculin under test and at least three dilutions of the standard preparation in isotonic buffer solution containing 0.0005% (w/v) polysorbate 80 (Tween 80). Choose the dilutions so that the reactions produced have diameters of not less than 8 mm and not more than 25 mm. Allocate the dilutions to the injection sites randomly according to a Latin square design. The dilutions correspond to 0.001, 0.0002 and 0.00004 mg of protein in a final dose of 0.2 ml, injected intradermally.

At 24 hours, the diameters of the reactions are measured and the results are calculated using standard statistical methods, taking the diameters to be directly proportional to the logarithms of the concentrations of the tuberculins. The estimated potency must be not less than 75% and not more than 133% of the potency stated on the label. The test is not valid unless the fiducial limits of error ( $p = 0.95$ ) are not less than 50% and not more than 200% of the estimated potency. If the batch fails a potency test, the test may be repeated one or more times provided that the final estimate of potency and of fiducial limits is based on the combined results of all the tests.

It is recommended that avian tuberculin should contain the equivalent of at least 25,000 IU/ml or approximately 0.5 mg protein per ml, giving a dose for practical use of 2500 IU/0.1 ml.

### 3. Requirements for authorisation/registration/licensing

#### 3.1. Manufacturing process

The manufacturing process should follow the requirements of European Pharmacopoeia (2000) or other international standards.

#### 3.2. Safety requirements

##### 3.2.1. Target and non-target animal safety

Antimicrobial preservatives or other substances that may be added to a tuberculin, must have been shown not to impair the safety and effectiveness of the product. The maximum permitted concentrations for phenol is 0.5% (w/v) and for glycerol it is 10% (v/v). The pH should be between 6.5 and 7.5.

##### 3.2.2. Precautions (hazards)

Experience both in humans and animals led to the observation that appropriately diluted tuberculin injected intradermally results in a localised reaction at the injection site without generalised manifestations. Even in very sensitive persons, severe, generalised reactions are extremely rare and limited.

#### 3.3. Stability

During storage, liquid avian tuberculin should be protected from the light and held at a temperature of 5°C ( $\pm 3^\circ\text{C}$ ). Freeze-dried preparations may be stored at higher temperatures (but not exceeding 25°C) protected from the light. During use, periods of exposure to higher temperatures or to direct sunlight should be kept at a minimum.

Provided the tuberculins are stored at a temperature of between 2°C and 8°C and protected from light, they may be used up to the end of the following periods subsequent to the last satisfactory potency test:

Liquid PPD tuberculins: 2 years; lyophilised PPD tuberculins: 8 years; HCSM (heat-concentrated synthetic-medium) tuberculins diluted: 2 years.

## REFERENCES

- ANGUS R.D. (1978). Production of Reference PPD tuberculins for Veterinary use in the United States. *J. Biol. Stand.*, **6**, 221.
- COUSINS D., FRANCIS B. & DAWSON D. (1996). Multiplex PCR provides a low-cost alternative to DNA probe methods for rapid identification of *Mycobacterium avium* and *Mycobacterium intracellulare*. *J. Clin. Microbiol.*, **34**, 2331–2333.
- DVORSKA L., BULL T.J., BARTOS M., MATLOVA L., SVASTOVA P., WESTON R.T., KINTR J., PARMOVA I., VAN SOOLINGEN D. & PAVLIK I. (2003). A standardised restriction fragment length polymorphism (RFLP) method for typing *Mycobacterium avium* isolates links IS901 with virulence for birds. *J. Microbiol. Methods*, **55**, 11–27.
- DVORSKA L., MATLOVA L., AYELE W. Y., FISCHER O. A., AMEMORI T., WESTON R. T., ALVAREZ J., BERAN V., MORAVKOVA M. & PAVLIK I. (2007). Avian tuberculosis in naturally infected captive water birds of the Ardeidae and Threskiornithidae families studied by serotyping, IS901 RFLP typing and virulence for poultry. *Vet. Microbiol.*, **119**, 366–374.
- DVORSKA L., MATLOVA L., BARTOS M., PARMOVA I., BARTL J., SVASTOVA P., BULL T. J. & PAVLIK I. (2004). Study of *Mycobacterium avium* complex strains isolated from cattle in the Czech Republic between 1996 and 2000. *Vet. Microbiol.*, **99**, 239–250.
- DVORSKA L., PARMOVA I., LAVICKOVA M., BARTL J., VRBAS V. & PAVLIK I. (1999). Isolation of *Rhodococcus equi* and atypical mycobacteria from lymph nodes of pigs and cattle in herds with the occurrence of tuberculoid gross changes in the Czech Republic over the period of 1996–1998. *Veterinarni Medicina*, **44**, 321–330.
- EUROPEAN PHARMACOPOEIA (2000). Purified protein derivative (avian). In: European Pharmacopoeia, Fourth Edition. Editions of the Council of Europe, Strasbourg, France, 1694.
- GUERRERO C., BERNASCONI C., BURKI D., BODMER T. & TELENTI A. (1995). A novel insertion element from *Mycobacterium avium*, IS1245, is a specific target for analysis of strain relatedness. *J. Clin. Microbiol.*, **33**, 304–307.
- HAAGSMA J. & ANGUS R.D. (1995). Tuberculin production. In: *Mycobacterium bovis* Infections in Humans and Animals, Steele J.H. & Thoen C.O., eds. Iowa State University Press, Ames, USA, 73–84.
- INDERLIED C.B., KEMPER C.A. & BERMUDEZ L.E.M. (1993). The *Mycobacterium avium* complex. *Clin. Microbiol. Rev.*, **6**, 266–310.
- KAEVSKA M., SLANA I., KRALIK P. & PAVLIK I. (2010). Examination of *Mycobacterium avium* subsp. *avium* distribution in naturally infected hens by culture and triplex quantitative real time PCR. *Veterinarni Medicina*, **55**, 325–330.
- KAZDA J., PAVLIK I., FALKINHAM J. & HRUSKA K. (2009). *The Ecology of Mycobacteria: Impact on Animal's and Human's Health*, First Edition, Springer Science+Business Media BV, 520 pp. ISBN 978-1-4020-9412-5.
- KUNZE Z.M., PORTAELS F. & MCFADDEN J.J. (1992). Biologically distinct subtypes of *Mycobacterium avium* differ in possession of insertion sequence IS901. *J. Clin. Microbiol.*, **30**, 2366–2372.
- KIRSCHNER P., MEIER P.A. & BOTTGER E.C. (1993). Genotypic identification and detection of mycobacteria. In: *Diagnostic Molecular Microbiology*, Persing D.H., Smith T.F., Tenover F.C. & White T.C., eds. American Society for Microbiology, Washington DC, USA, 173–190.
- MIJS W., DE HAAS P., ROSSAU R., VAN DER LAAN T., RIGOUTS L., PORTAELS F. & VAN SOOLINGEN D. (2002). Molecular evidence to support a proposal to reserve the designation *Mycobacterium avium* subsp. *avium* to bird-type isolates and *M. avium* subsp. *hominissuis* for the human/porcine type of *M. avium*. *Int. J. Syst. Evol. Microbiol.*, **52**, 1505–1518.
- MORAVKOVA M., HLOZEK P., BERAN V., PAVLIK I., PREZIUSO S., CUTERI V. & BARTOS M. (2008). Strategy for the detection and differentiation of *Mycobacterium avium* species in isolates and heavily infected tissues. *Res. Vet. Sci.*, **85**, 257–264.

- PAVLIK I., MATLOVA L., DVORSKA L., BARTL J., OKTABCOVA L., DOCEKAL J. & PARMOVA I. (2003). Tuberculous lesions in pigs in the Czech Republic during 1990-1999: occurrence, causal factors and economic losses. *Veterinarni Medicina*, **48**, 113–125.
- PAVLIK I., MATLOVA L., DVORSKA L., SHITAYE J. E. & PARMOVA I. (2005). Mycobacterial infections in cattle and pigs caused by *Mycobacterium avium* complex members and atypical mycobacteria in the Czech Republic during 2000–2004. *Veterinarni Medicina*, **50**, 281–290.
- PAVLIK I., SVASTOVA P., BARTL J., DVORSKA L. & RYCHLIK I. (2000). Relationship between IS901 in the *Mycobacterium avium* complex strains isolated from birds, animals, humans, and the environment and virulence for poultry. *Clin. Diagn. Lab. Immunol.*, **7**, 212–217.
- POCKNELL A.M., MILLER B.J., NEUFELD J.L. & GRAHN B.H. (1996). Conjunctival mycobacteriosis in two emus (*Dromaius novaehollandiae*). *Vet. Pathol.*, **33**, 346–348.
- REALINI L., DE RIDDER K., HIRSCHL B. & PORTAELS F. (1999). Blood and charcoal added to acidified agar media promote the growth of *Mycobacterium genavense*. *Diagn. Microbiol. Infect. Dis.*, **34**, 45–50.
- RITACCO V., KREMER K., VAN DER LAAN T., PIJNENBURG J.E.M., DE HAAS P.E.W. & VAN SOOLINGEN D. (1998). Use of IS901 and IS1245 in RFLP typing of *Mycobacterium avium* complex: relatedness among serovar reference strains, human and animal isolates. *Int. J. Tuberculosis Lung Dis.*, **2**, 242–251.
- ROZANSKA M. (1965). Preparation of antigen for whole blood rapid agglutination test and its specificity for diagnosis of avian tuberculosis. *Bull. Vet. Inst. Pulawy*, **9**, 20–25.
- SAITO H., TOMIOKA H., SATO K., TASAKA H. & DAWSON D.J. (1990). Identification of various serovar strains of *Mycobacterium avium* complex by using DNA probes specific for *Mycobacterium avium* and *Mycobacterium intracellulare*. *J. Clin. Microbiol.*, **28**, 1694–1697.
- SHITAYE J.E., GRÝMOVA V., GRÝM M., HALOUZKA R., HORVATHOVA A., MORAVKOVA M., BERAN V., SVOBODOVA J., DVORSKA-BARTOSOVA L. & PAVLIK I. (2009). *Mycobacterium avium* subsp. *hominissuis* infection in a pet parrot. *Emerg. Inf. Dis.*, **15**, 617–619.
- SHITAYE J.E., HALOUZKA R., SVOBODOVA J., GRÝMOVA V., GRÝM M., SKORIC M., FICTUM P., BERAN V., SLANY M. & PAVLIK I. (2010). First isolation of *Mycobacterium genavense* in blue headed parrot (*Pionus menstruus*) imported from Surinam (South America) to the Czech Republic: a case report. *Veterinarni Medicina*, **55**, 339–347.
- SHITAYE J.E., MATLOVA L., HORVATHOVA A., MORAVKOVA M., DVORSKA-BARTOSOVA L., TREML F., LAMKA J. & PAVLIK I. (2008). *Mycobacterium avium* subsp. *avium* distribution studied in a naturally infected hen flock and in the environment by culture, serotyping and IS901 RFLP methods. *Vet. Microbiol.*, **127**, 155–164.
- SHITAYE J.E., PARMOVA I., MATLOVA L., DVORSKA L., HORVATHOVA A., VRBAS V. & PAVLIK, I. (2006). Mycobacterial and *Rhodococcus equi* infections in pigs in the Czech Republic between the years 1996 and 2004: the causal factors and distribution of infections in the tissues. *Veterinarni Medicina*, **51**, 497–511.
- SLANA I., KAEVSKA M., KRALIK P., HORVATHOVA A. & PAVLIK, I. (2010). Distribution of *Mycobacterium avium* subsp. *avium* and *M. a. hominissuis* in artificially infected pigs studied by culture and IS901 and IS1245 quantitative real time PCR. *Vet. Microbiol.*, **144**, 437–443.
- SOINI H., EEROLA E. & VILJANEN M.K. (1996). Genetic diversity among *Mycobacterium avium* complex Accu-Probe-positive isolates. *J. Clin. Microbiol.*, **34**, 55–57.
- TELL L.A., WOODS L. & CROMIE R.L. (2001). Tuberculosis in birds. *Rev. sci. tech. Off. int. Epiz.*, **20**, 180–203.
- THOREL M.F., HUCHZERMAYER H. & MICHEL A.L. (2001). *Mycobacterium avium* and *M. intracellulare* infection in mammals. *Rev. sci. tech. Off. int. Epiz.*, **20**, 204–218.
- THOREL M.F., HUCHZERMAYER H., WEISS R. & FONTAINE J.J. (1997). *Mycobacterium avium* infections in animals. Literature review. *Vet. Res.*, **28**, 439–447.
- THOREL M.F., KRICHEVSKY M. & LEVY-FREBAULT V.V. (1990). Numerical taxonomy of mycobactin-dependent mycobacteria, emended description of *Mycobacterium avium*, and description of *Mycobacterium avium* subsp.

*avium* subsp. nov., *Mycobacterium avium* subsp. *paratuberculosis* subsp. nov., and *Mycobacterium avium* subsp. *silvaticum* subsp. nov. *Int. J. Syst. Bacteriol.*, **40**, 254–260.

VAN INGEN J., AL HAJAJ SAM., BOERE M., AL RABIAH F., ENAIMI M., DE ZWAAN R., TORTOLI E., DEKHUIJZEN R. & VAN SOOLINGEN D. (2009). *Mycobacterium riyadhense* sp. nov.; a non-tuberculous species identified as *Mycobacterium tuberculosis* by a commercial line-probe assay. *Int. J. Syst. Evol. Microbiol.*, **59**, 1049–1053.

VAN SOOLINGEN D., BAUER J., RITACCO V., CARDOSO LEAO S., PAVLI I., VINCENT V., RASTOGI N., GORI A., BODMER T., GARZELLI C. & GARCIA M.J. (1998). IS1245 restriction fragment length polymorphism typing of *Mycobacterium avium* isolates: proposal for standardization. *J. Clin. Microbiol.*, **36**, 3051–3054.

WOLINSKY E. & SCHAEFER W.B. (1973). Proposed numbering scheme for mycobacterial serotypes by agglutination. *Int. J. Syst. Bacteriol.*, **23**, 182–183.

WORLD HEALTH ORGANIZATION (WHO) (1987). Requirements for Biological Substances No. 16, Annex 1: Requirement for Tuberculins. Technical Report Series No. 745, WHO, Geneva, Switzerland, 31–59.

\*  
\* \*

**NB:** There is currently (2022) no OIE Reference Laboratory for avian tuberculosis  
(please consult the OIE Web site for the current list:  
<https://www.woah.org/en/what-we-offer/expertise-network/reference-laboratories/#ui-id-3>).

**NB:** FIRST ADOPTED IN 1989 AS TUBERCULOSIS IN BIRDS. MOST RECENT UPDATES ADOPTED IN 2014.